HIGHLIGHTS
- who: Wojciech Wiese and colleagues from the Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland have published the paper: IRE1 Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies, in the Journal: Cancers 2022, 14, 2526. of /2022/
- what: Blood cancers, which comprise several types of leukemia, lymphomas, and myeloma, can develop from various types of blood cells at any level of their differentiation, and thus, they constitute a highly heterogeneous group of neoplasms.
- how: The MKC-8866 IRE1u03b1 inhibitor was tested in Philadelphia-positive (Ph+) ALL cells simultaneously . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.